Home Cart Sign in  
Chemical Structure| 1428327-31-4 Chemical Structure| 1428327-31-4

Structure of JNJ-47965567
CAS No.: 1428327-31-4

Chemical Structure| 1428327-31-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JNJ 47965567 is a potent and selective P2X7 antagonist (pIC50 values are 8.3, 7.5 and 7.2 for human, mouse and rat receptors respectively).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JNJ-47965567

CAS No. :1428327-31-4
Formula : C28H32N4O2S
M.W : 488.64
SMILES Code : O=C(NCC1(N2CCN(C3=CC=CC=C3)CC2)CCOCC1)C4=C(SC5=CC=CC=C5)N=CC=C4
MDL No. :MFCD28334214
InChI Key :XREFXUCWSYMIOG-UHFFFAOYSA-N
Pubchem ID :66553218

Safety of JNJ-47965567

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
microglia 1 µM 30 minutes reduced round/ameboid microglia and increased complex morphologies only in CTRL but not KO microglia Front Pharmacol. 2023 Apr 10;14:1148190
hippocampal neurons 0.1 μM and 0.3 μM 30 minutes To evaluate the effect of JNJ on IL-1β immunoreactivity. Results showed that JNJ increased IL-1β immunoreactivity in neuronal cell bodies. Neurobiol Dis. 2022 Jun 15;168:105689

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague Dawley rats Bz-ATP-induced IL-1β release model Subcutaneous injection 30 or 100 mg/kg Single dose, lasting 2 hours To evaluate the inhibitory effect of JNJ-47965567 on Bz-ATP-induced IL-1β release, showing significant inhibition at 100 mg·kg?1 dose. Br J Pharmacol. 2013 Oct;170(3):624-40
Mice Status epilepticus model Intraperitoneal injection 30 mg/kg Single dose, observed for 1 hour JNJ-47965567 significantly inhibited KA-induced behavioral and EEG seizure activity, delayed the onset of seizures, and reduced their duration. Theranostics. 2025 Feb 10;15(7):3159-3184
Lewis rats Experimental autoimmune encephalomyelitis (EAE) model Subcutaneous injection 30 mg/kg Single dose, lasting 30 minutes JNJ-47965567, as a P2X7R antagonist, blocked the uptake of [11C]SMW139 in the spinal cord, cerebellum, and brain stem in the EAE animal model, demonstrating the specific accumulation of the tracer. J Neuroinflammation. 2020 Oct 14;17(1):300
Mice Temporal lobe epilepsy model Intraperitoneal injection 30 mg/kg Twice daily for 5 days To evaluate the effect of JNJ-47965567 on spontaneous seizures. Results showed a significant reduction in seizure frequency during treatment, which persisted after drug withdrawal. J Neurosci. 2016 Jun 1;36(22):5920-32
CD-1 mice Normal mice Subcutaneous injection 30 mg/kg Single dose, assessed after 60 minutes To evaluate the effect of JNJ on IL-1β immunoreactivity in the hippocampus and seizure threshold. Results showed that JNJ increased IL-1β immunoreactivity in CA3 pyramidal neurons and lowered the seizure threshold. Neurobiol Dis. 2022 Jun 15;168:105689
Mice (C57BL/6J) AMPH-induced mania-like behavior model Intraperitoneal injection 30 mg/kg Once daily for 8 consecutive days JNJ-47965567 significantly reduced AMPH-induced hyperlocomotion, and this effect was independent of the IL-1β signaling pathway. iScience. 2024 Feb 20;27(3):109284

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.05mL

0.41mL

0.20mL

10.23mL

2.05mL

1.02mL

20.46mL

4.09mL

2.05mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories